A multicenter, retrospective study of accelerated venetoclax ramp-up in patients with relapsed/refractory chronic lymphocytic leukemia

Matthew S. Davids; Mazyar Shadman; Sameer A. Parikh; Chaitra Ujjani; Jennifer L. Crombie; Dingfeng Jiang; Cynthia Llamas; Dai Feng; Nicole Lamanna

doi:10.1002/ajh.26444

A multicenter, retrospective study of accelerated venetoclax ramp-up in patients with relapsed/refractory chronic lymphocytic leukemia

Matthew S. Davids, Mazyar Shadman, Sameer A. Parikh, Chaitra Ujjani, Jennifer L. Crombie, Dingfeng Jiang, Cynthia Llamas, Dai Feng, Nicole Lamanna

Hematology

Research output: Contribution to journal › Letter › peer-review

Original language	English (US)
Pages (from-to)	E105-E109
Journal	American journal of hematology
Volume	97
Issue number	3
DOIs	https://doi.org/10.1002/ajh.26444
State	Published - Mar 1 2022

ASJC Scopus subject areas

Hematology

Access to Document

10.1002/ajh.26444

Cite this

@article{abffa05423724bc2aab11e5a4a660f0b,

title = "A multicenter, retrospective study of accelerated venetoclax ramp-up in patients with relapsed/refractory chronic lymphocytic leukemia",

author = "Davids, {Matthew S.} and Mazyar Shadman and Parikh, {Sameer A.} and Chaitra Ujjani and Crombie, {Jennifer L.} and Dingfeng Jiang and Cynthia Llamas and Dai Feng and Nicole Lamanna",

note = "Funding Information: Medical writing support was provided by Hayley Ellis, PhD, of Fishawack Communications Ltd, part of Fishawack Health, and funded by AbbVie. Matthew S. Davids is a Scholar in Clinical Research from the Leukemia & Lymphoma Society. Jennifer L. Crombie is supported by a K12 (K12CA087723). Venetoclax (ABT-199/GDC-0199) is being developed in collaboration between AbbVie, Inc., and Genentech. AbbVie, Inc. sponsored the study, contributed to the analysis, and interpretation of the data, and participated in the writing, review, and approval of the manuscript. All authors had access to all relevant data. No honoraria or payments were made for authorship. Funding Information: Medical writing support was provided by Hayley Ellis, PhD, of Fishawack Communications Ltd, part of Fishawack Health, and funded by AbbVie. Matthew S. Davids is a Scholar in Clinical Research from the Leukemia & Lymphoma Society. Jennifer L. Crombie is supported by a K12 (K12CA087723). Venetoclax (ABT‐199/GDC‐0199) is being developed in collaboration between AbbVie, Inc., and Genentech. AbbVie, Inc. sponsored the study, contributed to the analysis, and interpretation of the data, and participated in the writing, review, and approval of the manuscript. All authors had access to all relevant data. No honoraria or payments were made for authorship. ",

year = "2022",

month = mar,

day = "1",

doi = "10.1002/ajh.26444",

language = "English (US)",

volume = "97",

pages = "E105--E109",

journal = "American Journal of Hematology",

issn = "0361-8609",

publisher = "Wiley-Liss Inc.",

number = "3",

}

TY - JOUR

T1 - A multicenter, retrospective study of accelerated venetoclax ramp-up in patients with relapsed/refractory chronic lymphocytic leukemia

AU - Davids, Matthew S.

AU - Shadman, Mazyar

AU - Parikh, Sameer A.

AU - Ujjani, Chaitra

AU - Crombie, Jennifer L.

AU - Jiang, Dingfeng

AU - Llamas, Cynthia

AU - Feng, Dai

AU - Lamanna, Nicole

N1 - Funding Information: Medical writing support was provided by Hayley Ellis, PhD, of Fishawack Communications Ltd, part of Fishawack Health, and funded by AbbVie. Matthew S. Davids is a Scholar in Clinical Research from the Leukemia & Lymphoma Society. Jennifer L. Crombie is supported by a K12 (K12CA087723). Venetoclax (ABT-199/GDC-0199) is being developed in collaboration between AbbVie, Inc., and Genentech. AbbVie, Inc. sponsored the study, contributed to the analysis, and interpretation of the data, and participated in the writing, review, and approval of the manuscript. All authors had access to all relevant data. No honoraria or payments were made for authorship. Funding Information: Medical writing support was provided by Hayley Ellis, PhD, of Fishawack Communications Ltd, part of Fishawack Health, and funded by AbbVie. Matthew S. Davids is a Scholar in Clinical Research from the Leukemia & Lymphoma Society. Jennifer L. Crombie is supported by a K12 (K12CA087723). Venetoclax (ABT‐199/GDC‐0199) is being developed in collaboration between AbbVie, Inc., and Genentech. AbbVie, Inc. sponsored the study, contributed to the analysis, and interpretation of the data, and participated in the writing, review, and approval of the manuscript. All authors had access to all relevant data. No honoraria or payments were made for authorship.

PY - 2022/3/1

Y1 - 2022/3/1

UR - http://www.scopus.com/inward/record.url?scp=85122356964&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85122356964&partnerID=8YFLogxK

U2 - 10.1002/ajh.26444

DO - 10.1002/ajh.26444

M3 - Letter

C2 - 34929063

AN - SCOPUS:85122356964

SN - 0361-8609

VL - 97

SP - E105-E109

JO - American Journal of Hematology

JF - American Journal of Hematology

IS - 3

ER -

A multicenter, retrospective study of accelerated venetoclax ramp-up in patients with relapsed/refractory chronic lymphocytic leukemia

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this